PMV Pharmaceuticals stock gains on HC Wainwright buy rating and 5 dollar target

PMV Pharmaceuticals stock reacts to a fresh buy rating and a 5 dollar price target reaffirmed by HC Wainwright, with the shares trading near 1.24 dollars and a moderate buy consensus among analysts.

PMV Pharmaceuticals stock (ISIN US7301281085) is drawing investor attention on September 4, 2026 after analysts reiterated a positive view on the company, with the shares trading around 1.24 dollars on the Nasdaq and a fresh buy rating accompanied by a 5.00 dollar price target according to recent analyst data.

Analyst rating and price targets

According to a rating update summarized by Gurufocus on September 4, 2026, HC Wainwright reiterated its buy rating on PMV Pharmaceuticals and maintained a price target of 5.00 dollars per share, signaling that the broker expects the stock to more than triple from the current trading level.

Market data compiled by MarketBeat on September 4, 2026 show that PMV Pharmaceuticals shares opened at 1.24 dollars, while the same overview cites an average analyst rating of moderate buy and a consensus price target of 4.33 dollars per share, slightly below HC Wainwright's more optimistic 5.00 dollar target.

Stock performance and investor perspective

In its detailed coverage on September 4, 2026, MarketBeat's PMVP stock overview lists PMV Pharmaceuticals at around 1.25 dollars intraday, reflecting a decline of roughly 2.71 percent at that snapshot and positioning the stock far below the cited consensus and HC Wainwright price targets, which underscores the gap between current market pricing and analyst expectations.

For investors, this spread between the approximately 1.24 to 1.25 dollar share price on September 4, 2026 and the 4.33 to 5.00 dollar range of analyst targets highlights a speculative opportunity but also the risk that the market is currently assigning to PMV Pharmaceuticals, given that the shares would need to gain more than 200 percent to reach the upper end of the broker estimates.

PMV Pharmaceuticals pipeline and focus

PMV Pharmaceuticals, Inc. focuses on developing targeted cancer therapies based on the modulation of p53, a key tumor suppressor protein that is frequently mutated in a wide range of solid tumors, with its clinical pipeline including small-molecule candidates designed to restore normal p53 function in cancer cells according to information available on the company profile and investor communications.

The company positions its lead programs in oncology indications where p53 mutations are prevalent, aiming to translate its precision medicine approach into improved outcomes for patients and, in turn, into long-term revenue growth once therapies progress through clinical development and achieve regulatory approval, which is a central element of the investment case for PMV Pharmaceuticals stock.

PMV Pharmaceuticals stock price snapshot

Based on the latest quote information presented by MarketBeat on September 4, 2026, PMV Pharmaceuticals stock trades on the Nasdaq under the ticker PMVP at approximately 1.25 dollars during the morning session, with earlier data showing an opening level of 1.24 dollars the same day, and these values serve as the current market reference for retail investors evaluating the shares.

PMV Pharmaceuticals stock facts

• Company: PMV Pharmaceuticals, Inc.
• ISIN: US7301281085
• Ticker: PMVP
• Trading venue: Nasdaq
• Price (as of September 4, 2026): 1.25 USD
• Sector / Industry: Biotechnology / Pharmaceuticals
• Index membership: Nasdaq composite